Oncimmune Holdings plc
ONC.L · LSE
8/31/2024 | 2/29/2024 | 8/31/2023 | 2/28/2023 | |
|---|---|---|---|---|
| Revenue | £1,553 | £1,186 | £28 | £1,124 |
| % Growth | 30.9% | 4,135.7% | -97.5% | – |
| Cost of Goods Sold | £778 | £730 | £0 | £780 |
| Gross Profit | £775 | £456 | £28 | £344 |
| % Margin | 49.9% | 38.4% | 100% | 30.6% |
| R&D Expenses | £0 | £0 | £565 | £690 |
| G&A Expenses | £0 | £0 | £0 | £0 |
| SG&A Expenses | £3,243 | £1,214 | £481 | £3,163 |
| Sales & Mktg Exp. | £0 | £0 | £0 | £0 |
| Other Operating Expenses | £0 | £0 | £0 | £0 |
| Operating Expenses | £3,243 | £1,214 | £1,046 | £3,853 |
| Operating Income | -£2,468 | -£758 | -£1,018 | -£3,509 |
| % Margin | -158.9% | -63.9% | -3,635.7% | -312.2% |
| Other Income/Exp. Net | -£401 | -£348 | -£859 | -£542 |
| Pre-Tax Income | -£2,869 | -£1,106 | -£1,877 | -£4,051 |
| Tax Expense | -£470 | -£7 | £218 | £5 |
| Net Income | -£2,529 | -£1,099 | £8,160 | -£4,056 |
| % Margin | -162.8% | -92.7% | 29,142.9% | -360.9% |
| EPS | -0.034 | -0.015 | 0.11 | -0.058 |
| % Growth | -130.4% | -113.5% | 289.7% | – |
| EPS Diluted | -0.034 | -0.015 | 0.11 | -0.058 |
| Weighted Avg Shares Out | 74,142 | 74,142 | 74,142 | 69,931 |
| Weighted Avg Shares Out Dil | 74,142 | 74,142 | 74,142 | 69,931 |
| Supplemental Information | – | – | – | – |
| Interest Income | £17 | £0 | £0 | £0 |
| Interest Expense | £418 | £348 | £1,426 | £578 |
| Depreciation & Amortization | £109 | £154 | £42 | £780 |
| EBITDA | -£2,342 | -£604 | -£736 | -£2,693 |
| % Margin | -150.8% | -50.9% | -2,628.6% | -239.6% |